The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model-Reference-Cited by-同舟云学术

The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model

Published:2019-03-30 Issue:6 Volume:83 Page:1075-1082
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Higuchi Takashi,Miyake Kentaro,Sugisawa Norihiko,Oshiro Hiromichi,Zhang Zhiying,Razmjooei Sahar,Yamamoto Norio,Hayashi Katsuhiro,Kimura Hiroaki,Miwa Shinji,Igarashi Kentaro,Bouvet Michael,Singh Shree Ram^ORCID,Tsuchiya Hiroyuki,Hoffman Robert M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-019-03824-3.pdf

Reference41 articles.

1. Fletcher CD (2008) Undifferentiated sarcomas: what to do? And does it matter? A surgical pathology perspective. Ultrastruct Pathol 32(2):31–36

2. American Cancer Society (2019) Cancer facts and figs. American Cancer Society, Atlanta

3. Doyle LA (2014) Sarcoma classification: an update based on the 2013 World Health Organization Classification of tumors of soft tissue and bone. Cancer 120:1763–1774

4. Antoniou G, Lee ATJ, Huang PH, Jones RL (2018) Olaratumab in soft tissue sarcoma—current status and future perspectives. Eur J Cancer 92:33–39

5. Demoulin JB, Essaghir A (2014) PDGF receptor signaling networks in normal and cancer cells. Cytokine Growth Factor Rev 25(3):273–283